Edgewise Therapeutics Inc
EWTX
Market Cap$1.5B
Close$
$0.40
97.3% downside
Current Fair Value
97.3% downsideOvervalued by 97.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.47 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.45 |
| Beta | 0.37 |
| Outstanding Shares | 95,130,053 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.3 |
|---|---|
| PEG | -21.61 |
| Price to Sales | - |
| Price to Book Ratio | 3.71 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.63 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Edgewise Therapeutics Inc
19 employeesEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need....